Celularity and Fountain Life have announced a partnership to deliver investigational stem cell therapies in Florida, following the enactment of the state’s HB 1175 law. According to the companies, this collaboration aims to make certain stem cell-based interventions available to patients who meet specific eligibility criteria.
The company said that under the new law, patients can access investigational adult autologous and allogeneic stem cell treatments that have not yet received full FDA approval, provided certain safety and reporting requirements are met. Celularity plans to supply its placental-derived mesenchymal-like adherent stromal cells as part of the partnership.
According to Celularity, these cells are developed under current Good Manufacturing Practice (cGMP) conditions and are intended to support regenerative medicine applications. Fountain Life, which operates a network of precision diagnostic and wellness centers, will administer the therapies at its new facility in Florida.
The companies claim that the collaboration combines Celularity’s manufacturing capabilities with Fountain Life’s clinical delivery infrastructure to advance the availability of regenerative treatments. Celularity said that this approach aligns with its goal to expand patient access to innovative cell therapies while maintaining safety standards and compliance with state law.
The partnership marks an early example of how Florida’s new regulatory framework may accelerate the introduction of investigational regenerative medicine therapies outside traditional clinical trials, according to the companies.
